Graves' Disease & Thyroid Foundation

🗓️Last Chance to Register for 5/18 ATA® Alliance for Thyroid Patient Education Forum. Please share with your patients & colleagues - it's a great opportunity for patients to connect! Save Your Spot Now! ow.ly/vZyf50Z0ptJ #ThyroidAwareness #PatientEducation #ThyroidHealth

This might be of interest to our patient community, given that some patients with autoimmune thyroid disease also have PMOS (previously known as PCOS).

The challenges of #ThyroidEyeDisease (#TED) extend far beyond the surface. The ElevaTED survey gathered insights from more than 200 people living with TED and revealed the extensive hidden challenges people face. At Viridian, we are committed to making a meaningful difference.

Check out this insightful read from Medscape News Canada on AI and medical misinformation. (Login might be required to view, but registration should be free.) medscape.com/viewarticle/mi…

Today we announced positive topline results from our pivotal phase 3 REVEAL-2 clinical trial which evaluated elegrobart in chronic thyroid eye disease (TED). Learn more: investors.viridiantherapeutics.com/news/news-deta…

🦋 May is International Thyroid Awareness Month. The ATA® offers 50+ #thyroid brochures for all. 📢 Share and refer patients & colleagues to ow.ly/mXqf50YTgCP #ThyroidEducation #InternationalThyroidAwarenessMonth #ThyroidHealth @thyroidjournal @clinicalthyroid

"I was on set every day just really, really, really struggling to get through it all." Erin Moriarty recently spoke to The Hollywood Reporter about filming "The Boys" after a diagnosis of Graves' disease. hollywoodreporter.com/tv/tv-features…

We're headed to #AACE2026 this week! Our team will share data from our THRIVE and ElevaTED studies in #ThyroidEyeDisease. Visit us at booth # 093 to learn how we’re working to address unmet needs for patients with TED.

🗓️ Save the Date: ATA® Thyroid Patient Education Forum, May 18, 8-9:15 PM ET. Join us to connect with #thyroid experts and patients! Register free: ow.ly/QIKK50YMIeg #thyroid

If you are attending #AAES2026, today is the last day for the exhibit hall - stop by Ballroom 1 and say hello!

Our blog post warning other patient organizations about WebinarTV was featured in this post from @404mediaco: 404media.co/webinartv-secr…

2/2 ...regimen of 12 OBI injections, delivered two weeks apart. The trial met its primary endpoint in moderate-to-severe active TED, showing a 77% proptosis response over 24 weeks (versus 20% placebo).

1/2 Amgen has announced positive topline results from a Phase 3 trial of TEPEZZA (TM) delivered via an on-body injector (OBI). Patients treated w/ TEPEZZA currently receive eight infusions delivered three weeks apart, but the Phase 3 OBI trial tested a... amgen.com/newsroom/press…

2/2 Immunovant will continue to focus on IMVT-1402 (imeroprubart)​, an investigational drug for Graves' disease.

1/2 Immunovant, Inc. has announced topline results from its Phase 3 trial of batoclimab, noting that the investigational drug failed to meet its primary endpoint (≥2mm reduction in eye bulging after 24 weeks).​ immunovant.com/investors/news…

Here's additional info from @abbvie on the Armour Thyroid pricing coupon. (See the link below for details.)

@abbvie Thanks for the update!

@GDATF There is not a set coupon expiration date for the Good Rx Program. Offer subject to change or termination without notice. Full terms are available here: abbv.ie/368f37

Coverage changes may affect some patients using desiccated thyroid extracts. We have a self-pay option to support uninterrupted access. Patients and healthcare providers: visit abbv.ie/368f37

3/3 ...just over half of the participants in the 4-week group saw a complete resolution of double vision. A separate study is evaluating elegrobart for inactive (chronic) thyroid eye disease, with results expected later this year.

2/3 The trial included separate arms with 4-week and 8-week treatment regimens versus a placebo group. The 4-week and 8-week groups saw "meaningful" improvement in proptosis (bulging) versus placebo, and...

1/3 @ViridianThera has announced positive topline results for the Phase 3 trial of elegrobart, an investigational drug for active thyroid eye disease that is administered via subcutaneous injection.  ophthalmologytimes.com/view/phase-3-t…